BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22239437)

  • 1. Targeting the Fas/FasL signaling pathway in cancer therapy.
    Villa-Morales M; Fernández-Piqueras J
    Expert Opin Ther Targets; 2012 Jan; 16(1):85-101. PubMed ID: 22239437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
    Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
    Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpressed exogenous IL-4 And IL-10 paradoxically regulate allogenic T-cell and cardiac myocytes apoptosis through FAS/FASL pathway.
    Furukawa H; Oshima K; Tung T; Cui G; Laks H; Sen L
    Transplantation; 2008 Feb; 85(3):437-46. PubMed ID: 18301335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
    Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
    Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells.
    Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K
    Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fas signalling pathway and its role in the pathogenesis of cancer.
    Houston A; O'Connell J
    Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway.
    Yao Y; Li L; Huang X; Gu X; Xu Z; Zhang Y; Huang L; Li S; Dai Z; Li C; Zhou T; Cai W; Yang Z; Gao G; Yang X
    FEBS J; 2013 Jul; 280(14):3244-55. PubMed ID: 23615374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
    Mollinedo F; Gajate C
    Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas receptor-mediated apoptosis: a clinical application?
    Timmer T; de Vries EG; de Jong S
    J Pathol; 2002 Feb; 196(2):125-34. PubMed ID: 11793363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8.
    Yang C; Liu HZ; Fu ZX
    Cell Biol Int; 2012 Mar; 36(3):289-96. PubMed ID: 21888623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction.
    Li S; Zhou Y; Dong Y; Ip C
    Anticancer Res; 2007; 27(5A):3075-82. PubMed ID: 17970047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas and Fas ligand interactions in malignant disease.
    Owen-Schaub L; Chan H; Cusack JC; Roth J; Hill LL
    Int J Oncol; 2000 Jul; 17(1):5-12. PubMed ID: 10853011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
    Gordon N; Kleinerman ES
    Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seawater induces apoptosis in alveolar epithelial cells via the Fas/FasL-mediated pathway.
    Han F; Luo Y; Li Y; Liu Z; Xu D; Jin F; Li Z
    Respir Physiol Neurobiol; 2012 Jul; 182(2-3):71-80. PubMed ID: 22609371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Fas and FasL as mediators of anticancer chemotherapy.
    Poulaki V; Mitsiades CS; Mitsiades N
    Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells.
    Liu WH; Cheng YC; Chang LS
    J Cell Physiol; 2009 Jun; 219(3):642-51. PubMed ID: 19180563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-based therapeutic approaches targeting death receptors.
    French LE; Tschopp J
    Cell Death Differ; 2003 Jan; 10(1):117-23. PubMed ID: 12655300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.